Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

Name:	us-gaap_AccountsPayableCurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.

Consolidated Balance Sheets SFr in Thousands, $ in Thousands	Sep. 30, 2016 USD ($)	Sep. 30, 2016 CHF (SFr)	Dec. 31, 2015 USD ($)	Dec. 31, 2015 CHF (SFr)
Current assets:
Cash	$ 228,613		$ 155,961
Accounts receivable, including related party amounts of $459 and $0 as of September 30, 2016 and December 31, 2015, respectively (see Note 13)	2,092		339
Prepaid expenses and other current assets	946		540
Total current assets	231,651		156,840
Property and equipment, net	3,862		1,328
Equity method investment	35,686
Intangible assets, net	413		454
Restricted cash	3,153		700
Other non-current assets	3,888		101
Total assets	278,653		159,423
Current liabilities:
Accounts payable	1,943		1,584
Accrued expenses	12,402		8,430
Accrued tax liabilities	82		81
Deferred gain	63,608
Other current liabilities	62		60
Total current liabilities	78,097		10,155
Convertible loan, including accrued interest of $0 and $97 as of September 30, 2016 and December 31, 2015, respectively			38,336
Deferred revenue	76,949		75,090
Other non-current liabilities	574		445
Total liabilities	155,620		124,026
Commitments and contingencies (Note 7)
Shareholders' deficit:
Common shares, CHF 0.03 par value, 5,662,126 shares authorized and issued, and 5,307,845 shares outstanding, and 5,528,079 shares authorized, issued and outstanding in share capital at September 30, 2016 and December 31, 2015, respectively; 38,453,593 and 2,444,364 shares in conditional capital at September 30, 2016 and December 31, 2015, respectively	174		181
Treasury shares, at cost; 274,184 shares at September 30, 2016 and no shares at December 31, 2015	0	SFr 0	0	SFr 0
Additional paid-in capital	11,553		4,636
Accumulated deficit	(74,182)		(33,906)
Accumulated other comprehensive loss	(26)		(8)
Total CRISPR Therapeutics AG shareholders' deficit	(62,481)		(29,097)
Noncontrolling interest	(51)		(27)
Total shareholders' deficit	(62,532)		(29,124)
Total liabilities, redeemable convertible preferred shares and shareholders' deficit	278,653		159,423
Series A-1 Redeemable Convertible Preferred Shares [Member]
Redeemable convertible preferred shares:
Redeemable convertible preferred shares	1,169		1,169
Series A-2 Redeemable Convertible Preferred Shares [Member]
Redeemable convertible preferred shares:
Redeemable convertible preferred shares	10,394		10,394
Series A-3 Redeemable Convertible Preferred Shares [Member]
Redeemable convertible preferred shares:
Redeemable convertible preferred shares	45,368		22,518
Series B Redeemable Convertible Preferred Shares [Member]
Redeemable convertible preferred shares:
Redeemable convertible preferred shares	$ 128,634		$ 30,440